Gastric dumping syndrome epidemiology and demographics
|
Gastric dumping syndrome Microchapters |
|
Differentiating Gastric dumping syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastric dumping syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Gastric dumping syndrome epidemiology and demographics |
|
FDA on Gastric dumping syndrome epidemiology and demographics |
|
CDC on Gastric dumping syndrome epidemiology and demographics |
|
Gastric dumping syndrome epidemiology and demographics in the news |
|
Blogs on Gastric dumping syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Gastric dumping syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Incidence and prevalence varies depending on the procedure or disease leading to Dumping syndrome.
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- An estimated 20-50% of all patients who have undergone gastric surgery have some symptoms of dumping.
- However, only 1-5% are reported to have severe disabling symptoms.
- The incidence of significant dumping has been reported to be 6-14% in patients after truncal vagotomy and drainage and from 14-20% after partial gastrectomy.
- The incidence of dumping syndrome after proximal gastric vagotomy without any drainage procedure is less than 2%.
- Newer gastric operations, such as proximal gastric vagotomy (which produces minimal disturbance of gastric emptying mechanisms), are associated with a much lower incidence of postgastrectomy syndromes. In the pediatric population, dumping syndrome is described almost exclusively in children who have undergone Nissen fundoplication.
- Reductions in the need for elective gastric surgery have led to a decline in the frequency of postgastrectomy syndromes. A 10-fold reduction has occurred in elective operations for peptic ulcer disease in the last 20-30 years. Although this trend preceded the advent of histamine-2 receptor antagonists, these drugs and proton pump inhibitors have accelerated the decline. Helicobacter pylori treatment and eradication in patients with peptic ulcer disease have further decreased the need for surgery.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].